Approval · Notice of Compliance 30018 · 2023
AYBINTIO: Notice of Compliance 30018
Issued January 30, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30018
- Date
- January 30, 2023
- Company
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph Update
- Canadian reference product
- AVASTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AYBINTIO | Not yet assigned | — |
Medicinal ingredients
- BEVACIZUMAB 100 MG per 4ML
- BEVACIZUMAB 400 MG per 16ML